A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Peripheral Neuropathic Pain.

Trial Profile

A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Peripheral Neuropathic Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2009

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Feb 2009 Actual initiation date changed from Jan 2006 to Dec 2005 as reported by ClinicalTrials.gov.
    • 09 Jan 2008 Status changed from recruiting to completed.
    • 13 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top